» Articles » PMID: 33823783

Response to a Sexual Risk Reduction Intervention Provided in Combination with Hepatitis C Treatment by HIV/HCV Co-infected Men Who Have Sex with Men: a Reflexive Thematic Analysis

Abstract

Background: Hepatitis C virus reinfections in HIV-positive men-who-have-sex-with-men (MSM) challenge the effectiveness of antiviral treatment. To fight this problem, an adapted sexual risk reduction intervention was implemented within a hepatitis C treatment trial. Following this, the current study had two aims and describes 1) how the program was received by participants; and 2) their responses to the program regarding sexual risk taking. Based on the participants' input, we hoped to judge the intervention's potential for scale-up.

Methods: Seventeen participants who received the sexual risk reduction intervention in addition to hepatitis C treatment were recruited for semi-structured interviews six to 12 months post-intervention. We evaluated the responses via reflexive thematic analysis and applied the concept of sense-making.

Results: Giving hepatitis C a place and living without it again illustrates how participants received the program and how their experiences were altered by the impact of sense-making. Based on their responses, we allocated participants to three groups: 1. Avoid risks: get rid of hepatitis C for life. For these men, hepatitis C remained a life-threatening disease: they actively modified their risk behavior and felt supported by the intervention in maintaining their behavioral changes. 2. Minimize risks: live as long as possible without hepatitis C. In contrast to group 1, these men saw hepatitis C as a manageable disease. The intervention facilitated reflection on risks and how to develop behavioral changes that suited them individually. 3. Accept risks; live with the risk of hepatitis C. These men perceived behavioral changes as much more difficult than "easy" medical treatment. They expected to either undergo repeated rounds of treatment or stay HCV re-infected.

Conclusion: These results illustrate the diversity of men's responses and their decisions regarding sexual risk behavior after participating in a combination of antiviral treatment and a sexual risk reduction intervention. Two major aspects were identified: 1) Teachable moments, particularly at the time of diagnosis/treatment, could offer an opportunity to develop openness for behavioral change; 2) adapting sexual risk reduction interventions to sense-making patterns could help to improve its effectiveness. Support for reducing infection risk and raising awareness of preventative measures are additional benefits.

Trial Registration: Clinical Trial Number: NCT02785666 , 30.05.2016.

Citing Articles

Reinfection incidence and risk among people treated for recent hepatitis C virus infection.

Martinello M, Carson J, Van Der Valk M, Rockstroh J, Ingiliz P, Hellard M AIDS. 2023; 37(12):1883-1890.

PMID: 37467042 PMC: 10529102. DOI: 10.1097/QAD.0000000000003651.


Evaluating interventions to reduce behaviour associated with HCV reinfection in men who have sex with men: study protocol for a non-blinded, phase 2, randomised trial.

Hage K, Boyd A, Davidovich U, Zantkuijl P, Hoornenborg E, Matser A Trials. 2023; 24(1):193.

PMID: 36922871 PMC: 10015546. DOI: 10.1186/s13063-023-07161-y.


Feasibility of using Facebook for HIV prevention: Implications for translational research among justice-involved women who use drugs in rural Appalachia.

Staton M, Dickson M, Pike E, Young S J Clin Transl Sci. 2023; 6(1):e127.

PMID: 36590363 PMC: 9794968. DOI: 10.1017/cts.2022.497.


Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.

Prinsenberg T, Illidge J, Zantkuijl P, Bedert M, Prins M, Van Der Valk M PLoS One. 2022; 17(2):e0263654.

PMID: 35180246 PMC: 8856530. DOI: 10.1371/journal.pone.0263654.

References
1.
Soriano V, Labarga P, Fernandez-Montero J, de Mendoza C, Esposito I, Benitez-Gutierrez L . Hepatitis C cure with antiviral therapy--benefits beyond the liver. Antivir Ther. 2015; 21(1):1-8. DOI: 10.3851/IMP2975. View

2.
Apers L, Vanden Berghe W, De Wit S, Kabeya K, Callens S, Buyze J . Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015; 68(5):585-93. DOI: 10.1097/QAI.0000000000000528. View

3.
Schmidt A, Bremer V . Response to the calculation of population attributable fractions (PAFs) of risk factors for hepatitis C transmission. AIDS. 2016; 30(10):1683-4. DOI: 10.1097/QAD.0000000000001090. View

4.
Ghisla V, Scherrer A, Nicca D, Braun D, Fehr J . Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000-2016: a systematic review and meta-analysis. Infection. 2016; 45(3):309-321. DOI: 10.1007/s15010-016-0975-y. View

5.
Salazar-Vizcaya L, Kouyos R, Zahnd C, Wandeler G, Battegay M, Darling K . Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. Hepatology. 2016; 64(6):1856-1869. PMC: 5132019. DOI: 10.1002/hep.28769. View